Cyclacel Pharmaceuticals Inc. (CYCC) Is Spiking Higher On CYC065 News

Cyclacel Pharmaceuticals Inc. (CYCC) announced Monday morning that preclinical data of CYC065 showed that it substantially inhibited growth, triggered apoptosis, and induced anaphase catastrophe in murine and human lung cancer cells with known high metastatic potential.

Cyclacel Pharmaceuticals gapped up at the open Monday and has spiked higher in the last 15 minutes on increased volume. Shares are now up 2.13 at $5.81. The stock has surged to over a 1-month high and has re-crossed its 50 and 200-day moving averages.

For comments and feedback contact: editorial@rttnews.com

Business News

Looking to Invest in the Best Biotech Stocks? Subscribe to RTT Biotech Investor.
Follow RTT